EKTA-BNasdaq StockholmHealth CareIFRS · SEK

Elekta B

Elekta is a global leader in radiotherapy solutions, specializing in advanced technologies to treat cancer and neurological diseases. The company is renowned for its innovative products like the Elekta Evo linear accelerator and the Elekta ONE software suite, which enhance treatment efficiency and patient outcomes. Elekta's offerings are supported by AI-driven services and a robust global network, making it a key player in the radiotherapy market. Headquartered in Stockholm, Sweden, Elekta operates across multiple regions, contributing to its strong market presence and financial performance.

Ask about the company
Revenue16.7bn SEK
−7.2 %y/y
Operating profit (EBIT)890m SEK
−56.4 %y/y
EBIT margin5.3%
−6.0 ppy/y
Net income240m SEK
−81.6 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

05101520bn SEK2020: 13.8 bn SEK2020: EBIT 1.9 bn SEK20202021: 14.5 bn SEK2021: EBIT 1.6 bn SEK20212022: 16.9 bn SEK2022: EBIT 1.4 bn SEK20222023: 18.1 bn SEK2023: EBIT 2.0 bn SEK20232024: 18.0 bn SEK2024: EBIT 2.0 bn SEK20242025: 16.7 bn SEK2025: EBIT 0.89 bn SEK202516.70.89
RevenueOperating profit (EBIT)
Ask Clarifo about Elekta B

Business

Share of revenue
Linear Accelerators40 %

Includes Elekta Evo and other advanced radiotherapy equipment.

Software Solutions30 %

Comprises Elekta ONE and other software for treatment planning and management.

AI-supported Services15 %

AI-driven services to enhance treatment efficiency.

Specialty Products15 %

Includes niche radiotherapy products for specific treatments.

Customers

Elekta serves a diverse range of customers primarily in the healthcare sector, including hospitals, cancer treatment centers, and clinics worldwide. These customers rely on Elekta's advanced radiotherapy solutions to improve patient outcomes and operational efficiency. The company's products are particularly valued for their innovative technology and ability to integrate with existing healthcare systems. Elekta's AI-supported services further enhance the appeal to customers seeking cutting-edge treatment solutions. The company's strong presence in both developed and emerging markets allows it to cater to a wide array of healthcare providers.

Hospitals

Purchase advanced radiotherapy equipment to enhance treatment capabilities.

Cancer Treatment Centers

Utilize Elekta's solutions for improved patient outcomes.

Clinics

Adopt AI-supported services for operational efficiency.

Strategy

Elekta's strategic priorities focus on expanding its software offerings and enhancing its product portfolio with innovative solutions like the Elekta Evo. The company aims to leverage AI and digital technologies to improve treatment efficiency and patient outcomes. Elekta is also committed to maintaining strong financial performance through price increases and cost management. The company is actively exploring partnerships and collaborations to expand its global reach and market share. These strategic initiatives are designed to position Elekta as a leader in the radiotherapy market, driving long-term growth and competitiveness.

Expand software offeringsMedium term

To enhance treatment planning and management capabilities.

Leverage AI technologiesLong term

To improve treatment efficiency and outcomes.

Global market expansionLong term

To increase market share and reach new customers.

Geography

Elekta operates globally with significant market presence in the Americas, EMEA, and APAC regions. The company has a strong foothold in Europe, which is a key market for its innovative product launches. In APAC, Elekta experiences growth across most markets, although the Chinese market remains challenging. The Americas, particularly the U.S., have shown weaker sales, impacted by market conditions and regulatory factors. Elekta's global operations are supported by strategic manufacturing and supply centers that manage currency exposure and cost efficiencies.

Risks

Elekta faces several risks, including geopolitical tensions that may affect its operations and partnerships in certain markets. Currency fluctuations and economic uncertainties in key regions like the U.S. and China pose additional challenges. The company is also exposed to regulatory risks, particularly in the U.S., where product approvals can impact sales. Industry-specific risks include technological advancements by competitors and changes in healthcare regulations. Elekta's financial performance is sensitive to these factors, which could affect its revenue and profitability.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Geopolitical tensions1Regulatory risks2Currency fluctuations3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Geopolitical tensionsImpact: HighLikelihood: Medium

    May impact local partnering and sales.

  2. Regulatory risksImpact: HighLikelihood: Medium

    Impact product approvals and sales in the U.S.

  3. Currency fluctuationsImpact: MediumLikelihood: Medium

    Affect financial performance and cost management.

Ask Clarifo about Elekta B

Accounting

Judgemental items
Revenue recognition

Impacts timing and method of revenue reporting.

Impact: critical

Intangible asset impairment

Affects asset valuations and financial statements.

Impact: high

Similar listed companies

Publicly listed companies with a comparable business focus.

Telia Company

TELIA · Telecommunications

Cloetta

CLA-B · Consumer Staples

SECTRA

SECT-B · Health Care

CellaVision

CEVI · Health Care

Carasent

CARA · Health Care

Evolent Health, Inc.

EVH · Services-Management Services

Last updated: 24/09/2026